Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing nitrate esters for treating ventricular hypertrophy or myocardial fibrosis

A technology of myocardial fibrosis and nitrate ester, applied in the new field of western medicine, can solve problems such as heart failure, sudden death, dilated cardiomyopathy, etc., and achieve the effect of easy acceptance, strong operability, and simple administration route

Active Publication Date: 2008-02-13
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although initial hypertrophy is a beneficial compensatory response to prolonged cardiac overload, persistent hypertrophy can eventually lead to dilated cardiomyopathy, heart failure, or sudden death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Inhibitory effect of isosorbide mononitrate on hypertensive myocardial hypertrophy in DOCA-salt type rats

[0016] The DOCA-salt type rat hypertensive myocardial hypertrophy model belongs to the endocrine hypertensive hypertrophy model, which is the low renin type. Add saline to deoxycorticosterone to form a volume overload hypertensive myocardial hypertrophy model.

[0017] 1. Experimental materials

[0018] 1.1 Drugs Isosorbide Mononitrate (Lunan Pharmaceutical Co., Ltd.) Sodium Chloride (Tianjin Shentai Chemical Co., Ltd. Batch Number 20040318 Specification 500g Analytical Pure) Normal Saline (Binzhou Pharmaceutical Factory Batch Number 04111304 Specification 500ml) Nifedipine (Surabaya Xierkang Pharmaceutical Co., Ltd. Batch No. 200410224 Specification 10mg·100 tablets)

[0019] 1.2 Instrument Sartorius Analytical Balance (Beijing Sartorius Instrument System Co., Ltd.) Electronic Scale (Shanghai Dahua Electronic Scale Factory)

[0020] 1.3 Animals SD rats, clean g...

Embodiment 2

[0033] Inhibitory effect of nitroglycerin on myocardial hypertrophy induced by L-thyroxine

[0034] Large doses of L-thyroxine can promote the synthesis of mRNA and protein in cardiomyocytes, thereby making cardiac muscle hypertrophy. ATP depletion increases oxygen consumption and decreases the density of myocardial capillaries, thereby increasing the distance for oxygen to diffuse from capillaries to the center of myocardial cells. Therefore, myocardial hypertrophy is prone to ischemia, and there are scattered ischemic lesions.

[0035] 1. Experimental materials

[0036]1.1 Nitroglycerin (Beijing Yimin Pharmaceutical Co., Ltd. batch number 20050607 specification 5mg / tablet) sodium carboxymethyl cellulose (Sinopharm Chemical Reagent Co., Ltd. batch number F20050302 specification 500g chemically pure) L-thyroxine sodium tablet (Germany Merck company batch number 3600601 specification 50 μg / tablet) MDA kit and SOD kit were purchased from Nanjing Jiancheng Institute of Bioengine...

Embodiment 3

[0058] Inhibitory effect of isosorbide dinitrate on stress-induced hypertension model in rats

[0059] Rat models of stress-induced hypertension were prepared by cold water stimulation combined with noise stress stimulation. The occurrence of stress hypertension is the result of the interaction of many factors in the body. For example, during the stress process, the renin-angiotensin system (RAS) function is hyperactive, the sympathetic tension increases, the adrenal medulla releases adrenaline and norepinephrine, etc., and some substances that have an antagonistic effect on the above functions An exception occurred in the synthesis or release of .

[0060] 1. Experimental materials

[0061] 1.1 Drug Isosorbide Dinitrate Sustained-release Capsules (self-made) absolute ethanol (Qingdao Haibin Chemical Reagent Factory, batch number 200511019, specification 500ml analytically pure)

[0062] 1.2 Instrument Sartorius Analytical Balance (Beijing Sartorius Instrument System Co., L...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

Description

Technical field [0001] The present invention belongs to the new technology of western medicine, and its characteristic is that the treatment of new clinical symptoms is added. Background technique [0002] Cardiac hypertrophy, or ventricular hypertrophy, left ventricular hypertrophy is an independent risk factor for cardiovascular system diseases. Since the 1980s, people have gradually realized that myocardial hypertrophy is the adaptive response of myocardial cells and myocardial interstitial cells to various stimuli (pressure load, stretch, neurohumoral factors, vasoactive peptides, cytokines, growth factors, etc.), It is the result of abnormal expression of a series of genes in cells and changes in cell phenotype. Myocardial hypertrophy and myocardial fibrosis can be said to be two aspects of a disease. Cardiac hypertrophy caused by factors such as hypertension is accompanied by myocardial fibrosis. [0003] Myocardial hypertrophy is a common pathological change in hype...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/34A61K31/21A61P9/04
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com